Track Easywell Biomedicals's long-term debt ($300M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), 1799.TWO shows a long-term debt of $300M. That compares with $300M in the prior-year period — up 1.4% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 1799.TWO's long-term debt is now $300M (was $300M) — a 1.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Easywell Biomedicals is outperforming or lagging.
Tracking 1799.TWO's long-term debt over time shows whether Easywell Biomedicals is scaling, shrinking, or reshaping that part of the business. The current reading is $300M That compares with $300M in the prior-year period — up 1.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Easywell Biomedicals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $300M) with ownership activity and broader fundamentals.